Genzyme Corporation (Nasdaq: GENZ) announced today that it has received a complete response letter from the FDA regarding...
Author: Genzyme
Archive
March 2, 2009
CRANBURY, N.J., Feb 27, 2009—Amicus Therapeutics announced today that the Company has suspended enrollment for the Phase 2...
Author: Amicus
Archive
February 26, 2009
CAMBRIDGE, Mass. – Genzyme Corporation (Nasdaq: GENZ) announced today that the European Commission has approved the production of...
Author: Genzyme
Archive
February 25, 2009
CAMBRIDGE, Mass. – Genzyme Corporation (Nasdaq: GENZ) announced today that the Committee for Medicinal Products for Human Use...
Author: Genzyme
Archive
February 20, 2009
As Genzyme previously stated in July and again in October 2008, due to greater than expected adoption and...
Author: Genzyme
Archive
January 14, 2009
As Genzyme previously stated in July 2008 and again in October 2008, due to greater than expected adoption...
Author: Genzyme
Archive
January 14, 2009
This guidance is being distributed to all treating physicians worldwide except those in the European Union (EU). Separate...
Author: IPA/Genzyme
Archive
January 14, 2009
Since the first market approval of Myozyme, the IPA has liaised directly with Genzyme LSD Therapeutics to insist...
Author: IPA
Archive
January 14, 2009
Since the first market approval of Myozyme, the IPA has liaised directly with Genzyme LSD Therapeutics to insist...
Author: IPA
Archive
January 14, 2009
The IPA has compiled a list of Frequently Asked Questions (FAQs) in order to help answer potentially questions...
Author: IPA
Archive
January 14, 2009
1 30 31 32 33 34 38